Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 2018292

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2018292

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide), By Application, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 66.38 billion in 2025 and is projected to reach USD 185.32 billion by 2033, growing at a CAGR of 12.4% from 2026 to 2033. GLP-1 receptor agonists have become an important therapeutic class for managing type 2 diabetes and obesity through mechanisms that enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.

These combined metabolic effects support glycemic control, sustained weight reduction, and improved cardiometabolic outcomes, increasing their clinical adoption. The rising global prevalence of diabetes and obesity continues to drive demand for advanced treatment options that address multiple disease pathways. The increasing integration of these therapies into clinical practice reflects growing confidence among healthcare providers in their long-term benefits and treatment effectiveness. In 2025, semaglutide received expanded clinical recognition with approval for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis, demonstrating the broadening therapeutic scope of GLP-1 therapies. Such developments highlight the transition of GLP-1 receptor agonists from glucose-lowering agents toward comprehensive metabolic disease management solutions. The growing burden of chronic metabolic disorders is expected to sustain strong market expansion over the coming years.

Pharmaceutical research and development activities remain a major factor supporting innovation in the GLP-1 receptor agonist market, with companies focusing on improved efficacy, convenience, and patient adherence. Advancements in oral drug delivery technologies have created new opportunities to expand patient access beyond injectable therapies. In 2024, Pfizer selected a preferred once-daily modified-release formulation of danuglipron based on pharmacokinetic study results, reflecting continued progress in oral GLP-1 development. Licensing collaborations also strengthened the pipeline, with AstraZeneca partnering for oral GLP-1 candidates targeting obesity and cardiometabolic conditions. These innovations aim to improve treatment adherence by addressing patient preference for oral medications while maintaining therapeutic effectiveness. Expanding clinical pipelines and new formulation technologies are expected to enhance competition and diversify available treatment options. Continued research investment is likely to support future product approvals and broaden the clinical applications of GLP-1 receptor agonists across metabolic disorders.

Growing awareness of chronic disease management and weight-related health risks has increased patient interest in GLP-1 receptor agonist therapies. Educational programs and clinical initiatives have improved understanding of early intervention strategies and long-term management of metabolic health. In 2024, Amylyx Pharmaceuticals advanced the development of Avexitide, a therapy targeting conditions associated with hyperinsulinemic hypoglycemia, with plans for late-stage clinical evaluation beginning in 2025. Digital health programs and disease management platforms have also integrated GLP-1 therapies into structured treatment approaches to improve patient outcomes. Rising consumer awareness of the benefits of weight management has further expanded demand beyond traditional diabetes populations. The availability of newer therapeutic indications and expanding clinical evidence continues to strengthen adoption among both patients and healthcare providers. These factors collectively support the sustained growth of the GLP-1 receptor agonist industry through 2026 and beyond.

Global GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 receptor agonist market report based on product, application, route of administration, distribution channel, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Semaglutide (Ozempic, Wegovy, Rybelsus)
  • Tirzepatide (Mounjaro, Zepbound)
  • Dulaglutide (Trulicity)
  • Liraglutide (Victoza, Saxenda)
  • Others (Byetta, Bydureon, SOLIQUA)
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Type 2 Diabetes Mellitus
  • Obesity / Chronic Weight Management
  • Cardiovascular Risk
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectable / Parenteral
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68038-694-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Semaglutide (Ozempic, Wegovy, Rybelsus)
    • 4.4.1. Semaglutide (Ozempic, Wegovy, Rybelsus) Market, 2021 - 2033 (USD Million)
  • 4.5. Tirzepatide (Mounjaro, Zepbound)
    • 4.5.1. Tirzepatide (Mounjaro, Zepbound) Market, 2021 - 2033 (USD Million)
  • 4.6. Dulaglutide (Trulicity)
    • 4.6.1. Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
  • 4.7. Liraglutide (Victoza, Saxenda)
    • 4.7.1. Liraglutide (Victoza, Saxenda) Market, 2021 - 2033 (USD Million)
  • 4.8. Others (Byetta, Bydureon, SOLIQUA)
    • 4.8.1. Others (Byetta, Bydureon, SOLIQUA) Market, 2021 - 2033 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Business Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Type 2 Diabetes Mellitus
    • 5.4.1. Type 2 Diabetes Mellitus Market, 2021 - 2033 (USD Million)
  • 5.5. Obesity / Chronic Weight Management
    • 5.5.1. Obesity / Chronic Weight Management Market, 2021 - 2033 (USD Million)
  • 5.6. Cardiovascular Risk
    • 5.6.1. Cardiovascular Risk Market, 2021 - 2033 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Injectable / Parenteral
    • 6.4.1. Injectable / Parenteral Market, 2021 - 2033 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 8.4. North America
    • 8.4.1. North America GLP-1 Receptor Agonist Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Eli Lilly and Company
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sanofi
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Novo Nordisk A/S
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. AstraZeneca
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Teva Pharmaceutical Industries Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Glenmark Pharmaceuticals
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
Show more
Product Code: GVR-4-68038-694-3

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global GLP-1 receptor agonist market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 5 Global GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 Global GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America GLP-1 receptor agonist market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 10 North America GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 11 North America GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 12 North America GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S. GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 14 U.S. GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 15 U.S. GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 U.S. GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 18 Canada GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 19 Canada GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Canada GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 22 Mexico GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 23 Mexico GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 Mexico GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe GLP-1 receptor agonist market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 27 Europe GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 28 Europe GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Europe GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 31 UK GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 32 UK GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 UK GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 35 Germany GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 36 Germany GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 37 Germany GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 39 France GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 40 France GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 France GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 43 Italy GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 44 Italy GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Italy GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 47 Spain GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 48 Spain GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 49 Spain GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 51 Norway GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 52 Norway GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 53 Norway GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 55 Denmark GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 56 Denmark GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 Denmark GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 59 Sweden GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 60 Sweden GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Sweden GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific GLP-1 receptor agonist market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific GLP-1 receptor agonist market, by product, 2021 - 2033 (USD
  • Table 64 Asia Pacific GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 68 Japan GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 69 Japan GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Japan GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 72 China GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 73 China GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 China GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 76 India GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 77 India GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 78 India GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 80 Australia GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 81 Australia GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 82 Australia GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 84 South Korea GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 85 South Korea GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Korea GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 88 Thailand GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 89 Thailand GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 Thailand GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America GLP-1 receptor agonist market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 93 Latin America GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 94 Latin America GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Latin America GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 97 Brazil GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 98 Brazil GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 99 Brazil GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 101 Argentina GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 102 Argentina GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 103 Argentina GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa GLP-1 receptor agonist market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 110 South Africa GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 111 South Africa GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 112 South Africa GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 118 UAE GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 119 UAE GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 120 UAE GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)
  • Table 122 Kuwait GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)
  • Table 123 Kuwait GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)
  • Table 124 Kuwait GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 GLP-1 receptor agonist market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 GLP-1 receptor agonist market dynamics
  • Fig. 11 GLP-1 receptor agonist market: Porter's five forces analysis
  • Fig. 12 GLP-1 receptor agonist market: PESTLE analysis
  • Fig. 13 Product market, 2021 - 2033 (USD Million)
  • Fig. 14 Semaglutide (Ozempic, Wegovy, Rybelsus) market, 2021 - 2033 (USD Million)
  • Fig. 15 Tirzepatide (Mounjaro, Zepbound) market, 2021 - 2033 (USD Million)
  • Fig. 16 Dulaglutide (Trulicity) market, 2021 - 2033 (USD Million)
  • Fig. 17 Liraglutide (Victoza, Saxenda) market, 2021 - 2033 (USD Million)
  • Fig. 18 Others (Byetta, Bydureon, SOLIQUA) market, 2021 - 2033 (USD Million)
  • Fig. 19 Application market, 2021 - 2033 (USD Million)
  • Fig. 20 Type 2 Diabetes Mellitus market, 2021 - 2033 (USD Million)
  • Fig. 21 Obesity / Chronic Weight Management market, 2021 - 2033 (USD Million)
  • Fig. 22 Cardiovascular Risk market, 2021 - 2033 (USD Million)
  • Fig. 23 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 24 Injectable / Parenteral market, 2021 - 2033 (USD Million)
  • Fig. 25 Oral market, 2021 - 2033 (USD Million)
  • Fig. 26 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 27 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 29 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 30 GLP-1 receptor agonist market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 39 Europe GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 69 Latin America GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 74 MEA GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait GLP-1 receptor agonist market, 2021 - 2033 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!